“The compound is used in Asia for an astonishing list of diseases, despite the fact that it’s extremely expensive.
The Asian form is also suboptimal as a Western drug candidate because it comes from pig pancreases and the urine of young humans. Using animal or urine sources is not just aesthetically distasteful, it introduces risks of contamination into the production process that tend to put off regulators.
DiaMedica solved that problem by developing a proprietary, genetically modified cell type that expresses enormous amounts of KLK1 at a fraction of the cost of existing cell technologies. Big Pharma had tried to do this for years, always failing.
These cells have allowed DiaMedica to synthesize a drug under standardized conditions that has enormous potential—not only as treatments for many diseases, but as a breakthrough anti-aging geroprotector”
“Think of recombinant tissue kallikrein, DiaMedica’s lead product, as being a blood-vessel opening, blood-flow promoting substance that is nature’s preferred way of enhancing perfusion (flow) in tissues. You don’t have to be a rocket scientist to think of disease states where flow is aberrant or altered or needs assistance, right? What if recombinant tissue kallikrein had a role in all or many of those settings? Stroke, heart attack, peripheral vascular disease, angina, hypertension, maybe even PULMONARY hypertension.”
Market Data 
Markets 
AI
